BREAKING NEWS......If at first you dont suceed, try, try, again!!!
AstraZeneca prepares fresh COVID push to regulators after antibody's phase 3 success By James Waldron
While AstraZeneca’s globally used COVID-19 vaccine is leaving the scene, the British Big Pharma is hoping it will be taking a fresh therapeutic option to regulators soon.
Results from the phase 3 SUPERNOVA study show that the company’s investigational long-acting antibody (LAA) sipavibart produced a statistically significant reduction in the incidence of symptomatic COVID‑19.
The global trial of 3,335 immunocompromised patients saw half receive a 300-mg intramuscular dose of sipavibart and the others receive either AstraZeneca’s previously authorized LAA combo COVID-19 treatment Evusheld or placebo.
The study had two primary endpoints: reducing the number of cases of COVID-19 caused by any variant of the virus and the relative risk reduction of infections caused by variants not containing the F456L mutation.
SUPERNOVA hit both these goals, said AstraZeneca, ALTHOUGH IT DIDNT PROVIDE ANY DETAILS OF THE DATA!! WE WANT TO HIDE THE NON PEER REVIEWED DATA FOR 75 YEARS (LOL)
